Stephen Salloway

Important considerations for APOE disclosure in AD risk assessment 3:00
Important considerations for APOE disclosure in AD risk assessment
Stephen Salloway • 10 Mar 2021
Barriers to major advances in the Alzheimer’s field 1:39
Barriers to major advances in the Alzheimer’s field
Stephen Salloway • 10 Mar 2021
Progress in Alzheimer’s disease: aducanumab, imaging, and blood biomarkers 2:53
Progress in Alzheimer’s disease: aducanumab, imaging, and blood biomarkers
Stephen Salloway • 10 Mar 2021
Online registries allow rapid recruitment of diverse populations for AD trials 1:46
Online registries allow rapid recruitment of diverse populations for AD trials
Stephen Salloway • 10 Mar 2021
The content of VJNeurology is intended for healthcare professionals